ImmuneOncia Therapeutics has entered into a manufacturing agreement with Lonza for late-stage clinical supply of Danburstotug (IMC-001). Danburstotug is a fully human monoclonal antibody designed as an immune checkpoint inhibitor targeting programmed death-ligand 1 (PD-L1) and is under clinical investigation for the treatment of relapsed or refractory NK/T-cell lymphoma.
Under the agreement, Lonza will deliver an integrated, end-to-end solution covering both drug substance and drug product. Drug substance will be manufactured at Lonza’s site in Slough, UK, while drug product development and clinical manufacturing will be carried out at its Basel and Stein, Switzerland, facilities. ImmuneOncia will leverage Lonza’s global manufacturing network, regulatory track record and end-to-end expertise to support Danburstotug through late clinical development and potential commercialization.
ImmuneOncia CEO Heung-Tae Kim said the company plans to target the rare cancer indication NK/T-cell lymphoma for early approval, adding that the collaboration validates Danburstotug’s technology and commercial value globally and is expected to lay the groundwork for future licensing and overseas market entry. Michael de Marco, Vice President of Commercial Development, Integrated Biologics at Lonza, said the partnership highlights Lonza’s commitment to supporting biotech pipelines through to commercialization, noting that its comprehensive capabilities from drug substance to drug product manufacturing will enable ImmuneOncia to focus on bringing Danburstotug to the global market.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!